TEG011 treatment leads to efficient tumor control of K562-HLA*A24 tumors, whereas it shows no toxicity in vivo in NSG-A24 transgenic mice. NOD.Cg-Prkdc Il2rg Tg(HLA-A24)3Dvs/Sz (NSG-A24) mice were injected with 1 × 10⁵ K562 HLA-A*24:02 Luciferase cells on day 0 followed by 1 × 10⁷ TEG011 or LM1 transduced T cells on days 1 and 6 (n = 10 per group). In parallel, non-tumor–bearing mice also received 1 × 10⁷ TEG011 or LM1 transduced T cells on days 1 and 6 (n = 5 per group). Overall survival of treated K562-HLA*A24 luciferase tumor-bearing mice for monitoring efficacy (A) and overall survival of non-tumor–bearing mice for monitoring toxicity (B) was recorded for 57 days. Data represent the mean ± SD of all mice in each group. Statistical significance was calculated by log-rank (Mantel-Cox) test; *P < .05.